Key Documents
FUND SUMMARY
The Rize Medical Cannabis and Life Sciences UCITS ETF (FLWR) seeks to invest in companies that potentially stand to benefit from the increased adoption of cannabis as a medicine, with a focus on companies in the biotechnology/pharma and hemp and cannabidiol (CBD) sectors. FLWR seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Foxberry Medical Cannabis & Life Sciences Index.
KEY INFORMATION
- AUM ($USD): 16,455,096
- TER: 0.65%
- ISIN: IE00BJXRZ273
- Base Code: FLWR
- SFDR Classification: Article 8
- MSCI ESG Rating: BBB

INVESTMENT CASE
Medical cannabis has the potential to help millions of people globally. The stigma is coming down, and the cannabis plant is metamorphosing from a vice steeped in political, legal and cultural controversy to a medicine hailed for its remarkable therapeutic applications. Today, the movement is backed by the tailwinds of favourable legislation, social acceptance, medical recognition and pharmaceutical applications. Cannabis-derived pharmaceutical medicines are now available to treat symptoms associated with multiple sclerosis, certain types of cancer and rare forms of childhood epilepsy, including Lennox-Gastaut syndrome and Dravet syndrome. Our purpose-built investment strategy and ETF – Europe’s first truly global medical cannabis ETF – provides investors with access to companies that are positively exposed to the revolution in cannabis-derived medicine. As the medical cannabis movement gathers steam, catalysed by breakthroughs in our understanding of cannabinoids and the corresponding trend towards liberalisation and legalisation, getting on the front foot of this megatrend has its perks for those who can spot the investment opportunity today.
WHY FLWR?
-
Favourable Growth Prospects
FLWR is Europe’s first truly global medical cannabis ETF, and provides investors with exposure to the global revolution in cannabis-derived medication and wellness products.
-
Powered by New Frontier Data®
FLWR is purpose-built in collaboration with New Frontier Data, an independent cannabis research and tech-driven analytics firm based in Washington, D.C., and leverages their unique insights and proprietary classification system of companies that have demonstrable exposure to the emerging medical cannabis and life sciences sector.
-
Unconstrained Approach
FLWR’s composition transcends classic sector, size and geographic classifications by tracking an emerging theme.
-
ETF Efficiency
In a single trade, FLWR delivers access to dozens of companies that are favourably positioned to ride the tailwinds of the medical cannabis and life sciences theme.
Thematic Classification
FLWR invests in companies within the eligible sub-sectors of the thematic classification for the global cannabis industry built by cannabis industry experts New Frontier Data. The classification is an enabling taxonomy designed for the investment and research communities with the aim of identifying the 7 key sectors within the global cannabis industry – 4 of which are eligible for selection by FLWR – including the eligible companies and business activities that stand to benefit from the increased adoption of cannabis as a medicine.
MEDICAL CANNABIS AND LIFE SCIENCES

Agriculture Technology and Supplies

Biotechnology/Pharma

Big Pharma

Hemp and CBD
Performance
Capital at risk. Past performance is not a reliable indicator of future results. The value of your investment and income generated will vary, your initial investment amount cannot be guaranteed. The return of your investment may increase or decrease as a result of currency fluctuations.
Cumulative | ETF | Index | Tracking Difference |
---|---|---|---|
Year to date | |||
1 month | |||
3 months | |||
6 months | |||
1 year | |||
Inception |
Capital at risk. Past performance is not a reliable indicator of future results. The value of your investment and income generated will vary, your initial investment amount cannot be guaranteed. The return of your investment may increase or decrease as a result of currency fluctuations.
Scroll
Top 10 Holdings
Name | ISIN | Weight | CCY |
---|---|---|---|
REVVITY INC | US7140461093 | 15.45 | USD |
SCOTTS MIRACLE-GRO CLASS’A’COM NPV | US8101861065 | 15.33 | USD |
JAZZ PHARMACEUTICALS PLC COM USD0.0001 | IE00B4Q5ZN47 | 15.01 | USD |
PERRIGO COMPANY LIMITED COM EUR0.001 | IE00BGH1M568 | 14.51 | USD |
CARA THERAPEUTICS INC COM | US1407551092 | 8.61 | USD |
GROWGENERATION CORP COM | US39986L1098 | 8.17 | USD |
ABBVIE INC COM | US00287Y1091 | 5.67 | USD |
TEVA PHARMACEUTICAL INDS LTD ADR | US8816242098 | 5.66 | USD |
NOVARTIS AG SPONSORED ADR | US66987V1098 | 5.49 | USD |
HYDROFARM HLDGS GROUP INC COM NEW | US44888K2096 | 1.54 | USD |
Full fund holdings
Scroll


Fund Details
Net Assets | USD 16,455,096 |
NAV per share | USD 2.2428 |
Shares Outstanding | 7,336,994 |
Total Expense Ratio | 0.65 |
Inception | 12/02/2020 |
ISIN | IE00BJXRZ273 |
Base Code | FLWR |
Base Currency | USD |
Index Name | Foxberry Medical Cannabis and Life Sciences Index / FXBYFLWR |
Thematic Classification | New Frontier Data Sector Classifications |
Index Replication Method | Physical – full replication |
Income Treatment | Accumulating |
No. of holdings | 15 |
UCITS | Yes |
Domicile | Ireland |
Issuer | Rize UCITS ICAV |
Promoter | Rize ETF Limited |
Manager | IQ EQ Fund Management (Ireland) Limited |
Investment Manager | IQ EQ Fund Management (Ireland) Limited |
Depositary / Custodian | Northern Trust Fiduciary Services (Ireland) Limited |
ISA Eligible (UK) | Yes |
SIPP Eligible (UK) | Yes |
Reporting Fund Status (UK) | Yes |
Equity Fund (DE) | Yes |
SFDR Classification | Article 8 |
Scroll
Registrations
- Austria
- Denmark
- Finland
- Germany
- Ireland
- Italy
- Luxembourg
- Netherlands
- Norway
- Spain
- Sweden
- Switzerland
- United Kingdom
Listings
Exchange | Currency | Listing Date | SEDOL | Bloomberg Ticker | RIC |
---|---|---|---|---|---|
Deutsche Börse Xetra | EUR | 17-Feb-20 | BJXRZL6 | BLUM GY | BLUG.DE |
London Stock Exchange | USD | 18-Feb-20 | BJXRZC7 | FLWR LN | FLWR.L |
London Stock Exchange | GBP | 18-Feb-20 | BK5TNN5 | FLWG LN | FLWG.L |
SIX Swiss Exchange | CHF | 09-Jul-20 | BJXRZF0 | FLWR SE | FLWR.S |
Scroll
Fund Documents
All Other DocumentsRisks
The Fund is vulnerable to cyclical declines in the cannabis sector.
Any change to existing applicable laws or regulations that currently enable companies to engage in cannabis-related business activities ("CRB Activities") would reduce the value of affected companies and the Fund.
Also, some companies may breach such applicable laws or regulations which may (1) cause them to be de-listed from stock exchanges and/or reduce their market value (and therefore reduce the Fund’s value or its ability to realise its investments) and/or (2) mean that capital gains or income derived from such companies cause the Fund and/or the Fund's investors to be in breach of anti-money laundering laws or other laws applicable to them respectively ("Applicable Laws").
The Fund may have exposure to the recreational consumer market for cannabis even though it does not intend to. This might mean that the capital gains or income derived from companies with this exposure cause the Fund and/or the Fund's investors to be in breach of Applicable Laws.
A change in any legal requirements relating to funds with cannabis exposure might require the Manager to stop marketing the Fund in certain countries, de-list the Fund’s Shares from certain stock exchanges; and/or close the Fund.
The Fund invests in pharmaceutical companies which may never generate revenue due to clinical trial failures and/or a lack of required approvals for new drugs. Such factors could severely reduce the values of affected companies and the Fund. The Fund also invests in small publicly traded companies which may be more vulnerable to adverse business or economic events and greater and more unpredictable price changes than larger companies.
The Fund invests in global equity securities. As such there is a risk of loss arising from exchange rate fluctuations or exchange control regulations.
Other: (1) Third party service providers (such as the ICAV’s depositary) may go bankrupt and fail to pay money due to the Fund or return property belonging to the Fund. (2) If the Index provider stops calculating the Index or if the Fund’s license to replicate the Index is terminated, the Fund may have to be closed. (3) It may not always be possible to buy and sell the Fund’s Shares on a stock exchange or at prices closely reflecting the Net Asset Value. (4) There is no capital guarantee or protection on the value of the Fund and investors can lose all the capital invested in the Fund. (5) Please refer to the “Risk Factors” section of the ICAV’s Prospectus and the Fund Supplement.